AMGN News and Press, Amgen Inc. From 06/07/24

2024-06-07 07:05:00 ET Summary Warren Buffett once opined on how to live off of dividends in retirement. We discuss a simple way to follow his advice on this. We also share how to further enhance the yield on this portfolio while still generating strong dividend growth and kee...

2024-06-06 20:59:58 ET Summary The Schwab U.S. Dividend Equity ETF has performed reasonably well over the years. However it has underperformed a similar strategy, which is buying a diversified portfolio of Dividend Aristocrat stocks. The Dividend Aristocrats have beaten the S&...

AMGEN TO PRESENT AT GOLDMAN SACHS 45TH ANNUAL GLOBAL HEALTHCARE CONFERENCE PR Newswire THOUSAND OAKS, Calif. , June 5, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 45 th Annual Global Healthcare Conference at 9:20 a.m. ET on Mo...

2024-06-05 10:27:05 ET Summary "The Dow® [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors... Sector representation...is also a consideration.”–Dow Jones & Co. The high...

2024-06-05 09:41:38 ET More on Amgen Amgen Is A Fantastic Dividend Growth Stock With A Weight-Loss Wild Card Amgen Stock: Poised To Break Out (Technical Analysis) Amgen, Inc. (AMGN) ATS and the Approval of IMDELLTRA Conference - (Transcript) SA Asks: Which we...

AMGEN ANNOUNCES POSITIVE RESULTS FOR PHASE 3 REGISTRATIONAL TRIAL EVALUATING UPLIZNA® (INEBILIZUMAB-CDON) FOR TREATMENT OF IMMUNOGLOBULIN G4-RELATED DISEASE (IgG4-RD) PR Newswire Data Show a Statistically Significant 87% Reduction in IgG4-RD Flares, With Primary and All K...

2024-06-04 14:46:03 ET Summary Revolution Medicines, Inc. stock has more than doubled since the market initially reacted negatively to a clinical update on its lead asset RMC-6236 in October 2023. The company's RAS(ON) inhibitors will be tested in two registrational trials for pan...

2024-06-04 07:30:00 ET Summary The obesity market is expected to reach $130 billion by 2030, benefiting companies like Eli Lilly and Novo Nordisk. Amgen, a biotech company, is experiencing innovation-fueled growth with impressive new products and international expansion. Amgen...

2024-06-04 04:20:17 ET Summary Cerevel Therapeutics agreed to be acquired by AbbVie on 12/06/23 for $45/s or ~$8.7B. CERE stock closed on Friday, May 31st at $40.74/s. This presents investors with a potential arbitrage play of over 10% on a deal that should close within the next 3...

AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE PR Newswire THOUSAND OAKS, Calif. , June 3, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Jefferies Global Healthcare Conference at 9:00 a.m. ET on Thursday , June 6, 2024. Peter Griffith...